A Multicentre, Prospective, Open-label Randomised Controlled Clinical Study Comparing the Efficacy and Safety of NRT6003 Injection and Traditional Meridian Embolism in Patients with Non-operable Hepatocellular Cancer in China

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 14 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NRT 6003 (Primary)
Indications Liver cancer
Focus Therapeutic Use
Acronyms CHANCE2506

Most Recent Events

07 Apr 2025 New trial record
06 Apr 2025 Planned number of patients changed from 6 to 108.
06 Apr 2025 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight